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EDITORIAL
Imaging liver metastases—size is important
Philip J A Robinson
St. James’s University Hospital, Leeds, UK
All metastases start out small, and treatment is more
likely to be effective if the disease is detected at an
early stage, so the current focus of imaging is to improve
our ability to find small lesions. Sixty years ago, the
most effective instrument for detecting liver metastases
was the surgeon’s hand during laparotomy. J C Goligher,
a former colleague in Leeds, followed up about 700
patients after resection of primary colorectal cancers, and
found 31 whose livers appeared normal at surgery, but
who came to autopsy within one month. Five of these
(16%) were found to have unsuspected liver metastases.
Forty years ago, Ozada & Pickren examined 150 autopsy
livers containing metastases and found that in 11% of
cases, the organs appeared normal to inspection and
palpation but showed deep-seated tumours on sectioning.
Twenty years ago, it became clear from follow up studies
after resection of colorectal cancer that about one third of
patients in whom the liver appeared normal at the time
of laparotomy would develop detectable liver metastases
within two years. Observation of tumour growth rates
indicates that the lesions were almost certainly present
in the liver at the time of surgical examination. During
the last 20 years, non-invasive imaging techniques have
improved to the degree that they are now at least as
accurate as direct surgical examination of the liver,
and even with the addition of intra-operative ultrasound
(IOUS) it is now relatively uncommon for our surgical
colleagues to discover lesions at the time of operation
that were not already detected by earlier imaging. In a
current study in my own department, 20% of patients
undergoing liver resection with IOUS were found to have
‘new’ metastases on CT in within 6 months. All this
suggests that surgical findings at laparotomy no longer
represent a suitable standard of reference for measuring
the accuracy of imaging. In order to show further
improvements in imaging, we need a more sensitive
reference standard.
The increasing use of surgical resection for liver
metastases, particularly from colorectal primaries, gives
us an opportunity to correlate imaging with histology
in more detail, but there are still limitations here.
Conventional pathologic examination of gross liver
specimens involves slicing the organ at 1 cm intervals,
but then employing the same methods as those used
by the surgeons at laparotomy—visual inspection, and
palpation. Pathologists may run into the same problem
faced by the radiologist with CT and MRI—that of
missing lesions which are smaller in size than the
thickness of the slice. The obvious answer is to
use thinner slices both in imaging and in pathologic
examination. This could lead to a rather odd situation
(which seems to be happening in my own institution)
where we radiologists think we are detecting more and
more small liver lesions, but the pathologist, using thinner
slices to examine the resected liver segments, is also
finding more smaller lesions, so our rates of detection are
apparently not improving.
Until recently, studies describing the accuracy of
imaging techniques did not usually indicate the size
distribution of the lesions they found, so sensitivity could
not be related to size. Recent work indicates that with
colorectal liver metastases, careful MRI or CT should
detect 95% or more of lesions larger than about 15 mm.
The real issue now is the accuracy of detection for
lesions smaller than this. One possible approach, which
would be independent of the quality of the pathologic
gold standard, would be to look at the distribution of
sizes amongst the lesions detected. A presentation at the
recent ESGAR/SGR meeting reported that almost 60%
of colorectal liver metastases were smaller than 20 mm at
the time of detection, and 30% were smaller than 10 mm.
If we can further increase the proportion of lesions that
are detected at this size range we can be confident that
our imaging techniques are improving.
The next problem we run into is the relatively frequent
incidence of small benign lesions in the liver. Studies
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dating back several years have shown that the majority
of sub-centimetre lesions found on CT, even in patients
with established malignant disease, remain stable over
prolonged observation and appear to be benign, although
pathologic confirmation is rarely obtained. With multi-
slice CT we are finding more and more smaller and
smaller lesions, which poses the same difficulty as that
created by the introduction of lung CT over 20 years
ago—most of these tiny lesions are benign, but their
imaging characteristics are overlapping and in some cases
indistinguishable from those of metastases. With MRI,
benign features are often demonstrable, but even so, the
prevalence of small benign malformations in the liver
adds an extra level of difficulty to the recognition of
sub-centimetre metastases. Although we will continue
to improve the detection and characterisation of sub-
centimetre lesions, there seems to be no prospect with
current imaging methods of finding liver metastases
smaller than about 2 mm. But do we need to?
Imaging is used not only to detect disease but also to
localise it. The main objective of localisation (possibly
the only objective) is to allow treatment by local
measures—whether surgery, radiotherapy, or other forms
of ablation. These types of treatment are only applicable
to disease of macroscopic dimensions, so once we are
dealing with sub-millimetre metastases, localisation may
become unimportant and only detection is needed to
allow systemic or regional chemo- or immuno-therapy.
We already know that colorectal liver metastases, even
when they are too small to be detected by surgical
examination at laparotomy or by conventional imaging,
produce changes in the relative proportions of arterial and
portal venous inflow into the liver. This disturbance in
liver perfusion was first shown 20 years ago by nuclear
medicine techniques, and later by Doppler ultrasound. At
the time, the mechanism for this blood flow disturbance
was not known, but the more recent demonstration of
angiogenesis in tumours of sub-millimetre size explains
these early perfusion changes. So far, the perfusion
techniques have not found wide usage, mostly because
the original encouraging results have been difficult to
reproduce in other centres. This is partly explained by
the fact that as with other physiological measurements,
the range of normal variation is enough to obscure small
pathologic changes. Further, it is not clear how much
tumour mass is needed to create the degree of perfusion
disturbance which can be measured externally, so even if
these approaches were reproducible and reliable, we still
need to establish the size range of lesions which might be
detectable.
Finally, the natural history of metastases at an even
earlier stage of growth is gradually being unravelled.
Experimental work on small animals many years ago
showed that very large numbers of tumour emboli
injected into the portal vein would produce only a
few liver metastases, suggesting the presence of active
biological defence mechanisms. Recent work from
a group in Boston, summarised at ESGAR/SGR by
Dr Kurskal, used an elegant technique of direct optical
microscopy of the mouse liver in vivo to demonstrate the
sequence of events at cellular level following the release
of tumour cells into the portal circulation. In brief, they
found that cancer cells were not mechanically trapped in
portal venules, but were phagocytosed by Kupffer cells
which then released cytokines, causing changes in the
local vascular endothelium which allowed tumour cells to
bind to and subsequently migrate through the vessel walls
to establish invasive growth. Although further elaboration
of the mechanisms involved is awaited, even these
early results suggest new approaches for detection by
molecular imaging techniques and for novel treatments.
In summary, we should now be able to detect, with
careful use of current MRI and CT, the vast majority
of colorectal liver metastases larger than 1–2 cm. In
order for imaging to be equally effective for lesions
in the 2–20 mm size range, we need to pursue further
refinements in our existing technologies. Lesions in the
size range of 0.2–2 mm are more likely to be treated by
regional or systemic immuno- or chemo-therapy, so we
don’t need to worry about localising them, only about
detecting their presence. This might best be achieved by
exploiting the perfusion changes associated with tumour
angiogenesis, but our techniques need to be more robust
than they are at present, and we also need to explore
the specificity of these vascular changes since similar
perfusion disturbances occur in other forms of liver
disease. For lesions at the earliest stage of growth (20–
200 µ), it appears likely that detection will require the
recognition of specific molecular or genetic markers and
again it will be the specificity of these markers which
determine the feasibility of detection by imaging, with
PET being the most likely of our current techniques to
contribute.
